{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Xiao B"],"funding":["American Heart Association","National Institute of Diabetes and Digestive and Kidney Diseases","NIDDK NIH HHS","National Institutes of Health","U.S. Department of Veterans Affairs"],"pagination":["1289-300.e1-19"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC3992175"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["146(5)"],"pubmed_abstract":["Background & aims
Nanoparticles have been explored as carriers of small interfering RNAs (siRNAs) and might be developed to treat patients with inflammatory bowel disease (IBD). Overexpression of CD98 on the surface of colonic epithelial cells and macrophages promotes the development and progression of IBD. We developed an orally delivered hydrogel that releases nanoparticles with single-chain CD98 antibodies on their surface (scCD98 functionalized) and loaded with CD98 siRNA (siCD98). We tested the ability of the nanoparticles to reduce levels of CD98 in the colons of mice with colitis.Methods
scCD98-functionalized siCD98-loaded nanoparticles were fabricated using a complex coacervation technique. We investigated the cellular uptake and lysosome escape profiles of the nano"],"journal":["Gastroenterology"],"pubmed_title":["Nanoparticles with surface antibody against CD98 and carrying CD98 small interfering RNA reduce colitis in mice."],"pmcid":["PMC3992175"],"funding_grant_id":["KO1-DK-097192","R01 DK071594","K01 DK097192","K01-DK-097192","R01-DK-071594","RO1-DK-071594","13POST16400004","R01 DK064711"],"pubmed_authors":["Ayyadurai S","Gewirtz AT","Merlin D","Charania MA","Zhang Z","Zhang Y","Viennois E","Baker MT","Zhang B","Xiao B","Laroui H"],"additional_accession":[]},"is_claimable":false,"name":"Nanoparticles with surface antibody against CD98 and carrying CD98 small interfering RNA reduce colitis in mice.","description":"Background & aims
Nanoparticles have been explored as carriers of small interfering RNAs (siRNAs) and might be developed to treat patients with inflammatory bowel disease (IBD). Overexpression of CD98 on the surface of colonic epithelial cells and macrophages promotes the development and progression of IBD. We developed an orally delivered hydrogel that releases nanoparticles with single-chain CD98 antibodies on their surface (scCD98 functionalized) and loaded with CD98 siRNA (siCD98). We tested the ability of the nanoparticles to reduce levels of CD98 in the colons of mice with colitis.Methods
scCD98-functionalized siCD98-loaded nanoparticles were fabricated using a complex coacervation technique. We investigated the cellular uptake and lysosome escape profiles of the nano","dates":{"release":"2014-01-01T00:00:00Z","publication":"2014 May","modification":"2025-04-05T10:47:26.783Z","creation":"2019-03-27T01:26:37Z"},"accession":"S-EPMC3992175","cross_references":{"pubmed":["24503126"],"doi":["10.1053/j.gastro.2014.01.056"]}}